Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide for Liver Fibrosis in Type 2 Diabetes
2023-504100-28-00Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatic fibrosis, metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM) comparing nicotinamide with placebo (2 arms). Primary endpoints: Change in liver stiffness by Fibroscan, Change in intrahepatic fat by CAP and 2 more. Planned start Jun 2023; status: authorised.
02
Drugs
nicotinamide
03
Conditions
hepatic fibrosismetabolic dysfunction-associated steatohepatitis (MASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-504100-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504100-28-00.